Medicenna Expands MDNA11 into Neoadjuvant Melanoma with NEO-CYT Trial
Event summary
- Medicenna’s MDNA11 featured in NEO-CYT trial presentation at ASCO 2026, evaluating its potential in neoadjuvant melanoma setting.
- NEO-CYT is a Phase 1b, multicenter trial enrolling up to 80 patients with high-risk, surgically resectable Stage IIIB/C/D melanoma.
- Trial compares MDNA11 combinations with current gold-standard ipilimumab plus nivolumab, with primary endpoint being Major Pathologic Response.
- MDNA11 clinical data updates from ABILITY-1 and NEO-CYT trials anticipated in H2 2026.
The big picture
Medicenna’s NEO-CYT trial represents a strategic shift into earlier-line, curative-intent melanoma treatment, capitalizing on the growing adoption of neoadjuvant immunotherapy. The trial’s focus on enhancing pathologic response rates addresses a critical unmet need, as current checkpoint therapies leave nearly 40% of patients without a meaningful response. Success in this setting could significantly expand MDNA11’s market potential beyond advanced-stage indications.
What we're watching
- Clinical Efficacy
- Whether MDNA11 can demonstrate superior Major Pathologic Response rates compared to current gold-standard therapies in the neoadjuvant setting.
- Commercial Strategy
- How Medicenna leverages NEO-CYT and ABILITY-1 data to position MDNA11 across multiple tumor types and treatment stages.
- Regulatory Pathway
- The pace at which positive NEO-CYT results could accelerate MDNA11’s development timeline and potential approvals.
Related topics